Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. AT-007 is a central nervous system penetrant ARI that Co. is developing for the treatment of metabolic diseases, including Galactosemia, a pediatric metabolic disease that affects how the body processes a simple sugar called galactose. AT-001 is an ARI with systemic exposure and peripheral nerve permeability that Co. is developing for the treatment of diabetic cardiomyopathy. AT-003 is an ARI designed to cross through the back of the eye when dosed orally for the treatment of diabetic retinopathy. The APLT stock yearly return is shown above.
The yearly return on the APLT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the APLT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|